文献速递临床试验与 GCP基础与转化研究

枸杞多糖补充对非酒精性脂肪肝患者影响的随机对照试验方案

Effect of Lycium barbarum polysaccharide supplementation in non-alcoholic fatty liver disease patients: study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2021-08-26

本研究为随机双盲安慰剂对照试验,计划在宁夏回族自治区人民医院体检中心招募50例经腹部超声、实验室检查和问卷调查确诊的非酒精性脂肪肝(NAFLD)患者,随机分为对照组(麦芽糊精安慰剂胶囊)和干预组(枸杞多糖补充胶囊),干预3个月。主要结局为干预后丙氨酸氨基转移酶(ALT)浓度缓解水平,次要结局包括肠道菌群丰度和多样性、肠道通透性、人口学特征和体成分、不良反应及依从性。

要点

  • 枸杞多糖作为潜在益生元,可能通过调节肠道菌群改善NAFLD。
  • 主要结局为干预3个月后ALT浓度缓解水平。
  • 试验采用双盲设计,患者、研究者和数据收集者均不知晓分组。

核心结论

  • 该试验旨在评估枸杞多糖补充调节肠道菌群对NAFLD患者的安全性和有效性。

研究设计与样本

  • 随机、双盲、安慰剂对照试验,计划招募50例经腹部超声、实验室检查和问卷调查确诊的NAFLD患者。
  • 干预组接受枸杞多糖补充胶囊,对照组接受麦芽糊精安慰剂胶囊,干预3个月。

关键数值与推荐

  • 主要结局指标为干预后ALT浓度缓解水平。
  • 次要结局包括肠道菌群丰度和多样性、肠道通透性、人口学特征和体成分、不良反应及依从性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Non-alcohol fatty liver disease (NAFLD) is the most common chronic liver disease in the world, with a high incidence and no effective treatment. At present, the targeted therapy of intestinal microbes for NAFLD is highly valued. Lycium barbarum polysaccharide (LBP), as the main active ingredient of Lycium barbarum, is considered to be a new type of prebiotic substance, which can improve NAFLD by regulating the gut microbiota. The purpose of this study is to evaluate the safety and efficacy of LBP supplementation in modulating gut microbiota for NAFLD patients. METHODS: This randomized, double-blind, placebo-control study will be conducted in the physical examination center of the Ningxia Hui Autonomous Region People's Hospital. A total of 50 patients with NAFLD confirmed by abdominal ultrasound, laboratory tests, and questionnaire surveys will be recruited and randomly assigned into the control group (maltodextrin placebo capsules) and the intervention group (LBP supplementation capsules) for 3 months. Neither patients, nor investigators, nor data collectors will know the contents in each capsule and the randomization list. The primary outcome measure is the level of ALT concentration relief after the intervention. Secondary outcomes include gut microbiota abundance and diversity, intestinal permeability, patient's characteristic demographic data and body composition, adverse effects, and compliance from patients. DISCUSSION: LBPs are potential prebiotics with the property of regulating host gut microbiota. Our previous studies have documented that LBP supplement can improve the liver damage and the gut microflora dysbiosis in NAFLD rats. This treatment would provide a more in-depth understanding of the effect of this LBP supplementation. TRIAL REGISTRATION: Chinese Clinical Trial Register, ChiCTR2000034740 . Registered on 17 July 2020.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Gao LL, Li YX, Ma JM, et al. Effect of Lycium barbarum polysaccharide supplementation in non-alcoholic fatty liver disease patients: study protocol for a randomized controlled trial. Trials. 2021. PMID: 34521466. doi:10.1186/s13063-021-05529-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。